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Osteoarthritis (OA) is a leading cause of 
chronic disability worldwide with a substan-
tial impact on healthcare economies.1 The 
hip is the most commonly affected joint after 
the knee, and hip arthroplasty provides a 
low-morbidity, cost-effective solution to the 
pain and functional impairment arising from 
the disease.2 The long-term survivorship of 
these prostheses is also generally good.3
So, where is the problem? The answer lies, 
at least in part, on the cumulative cost of the 
disease and its treatment on the economy. 
The lifetime risk of hip arthroplasty in west-
ern countries in 2013 was approximately 
10%, and this continues to increase.4 In 
2017, the number of hip arthroplasties 
reported to the National Joint Registry for 
England, Wales, and Northern Ireland was 
105 306. The current standard NHS tariff 
payment for a non-complex hip arthroplasty 
is approximately £6000. This equates to a 
direct treatment cost in this territory alone of 
more than £530 million per annum. This 
does not, however, include the overall eco-
nomic cost, which for OA as a whole is esti-
mated at 1% of annual gross national 
product, costing the United Kingdom econ-
omy £3.2 billion in lost production.
What can be done to make hip arthroplasty 
surgery more cost-effective?. The range of 
prosthesis construct combinations avail-
able is large; in England and Wales alone, 
there are over 800.5 Of these, in 2017 28.2% 
were of cemented fixation; 37.8% cement-
less; 30.3% hybrid (cemented stem); 3.1% 
reverse hybrid (cemented component); and 
0.6% were hip resurfacing procedures. Of 
bearing interfaces, 57.6% were metal on 
polyethylene; 37.8% were ceramic on poly-
ethylene; 9.0% were ceramic on ceramic; 
and less than 0.7% metal-on-metal. Given 
that these various combinations of pros-
theses have different pricing, and that 
their reoperation-free survival varies, there 
has been a strong move in the United 
Kingdom towards reducing the range of 
available prostheses by promoting those 
that are most cost-effective over the life of 
the patient. This ‘getting it right first time’ 
agenda is a logical solution for both patients 
at the population level and for the national 
economy. However, others argue that such 
a ‘one size fits all’ approach reduces health-
care to the economic consideration and 
stifles prosthesis innovation at a time when 
personalized care is also an important con-
cern. Nonetheless, the NHS best practice 
tariff for hip arthroplasty from 1 April 2019 
required that, at an institutional level, 80% 
of patients aged over 70 years receive either 
a fully cemented or hybrid prosthesis.
What about the younger patient with hip 
OA?. Increasing evidence shows us that 
hip OA is strongly heritable, with identified 
genetic variants accounting for 52% of that 
risk.6 Many of these variants modulate struc-
tural bone or cartilage genes responsible 
for normal joint development,6-9 raising the 
potential for novel therapeutic interventions. 
Synthetic biology approaches, gene editing, 
cellularised scaffolds, and other technolo-
gies are also bearing fruit in the preclini-
cal setting,10-12 as are novel investigational 
drugs targeting established OA pathways,13 
assisted by increased acceptance by regula-
tory authorities of structural endpoints for 
establishing their efficacy. However, these 
solutions will not form part of routine clinical 
care in the near future.
Recent data also suggest that the survivor-
ship of hip arthroplasty in the younger 
patients is better than previously antici-
pated.14 However, priorities and expectations 
vary between patients. Large diameter metal-
on-metal bearings are still favoured by some. 
While in selected young and active men, the 
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revision-free survival of these prostheses may be similar to 
conventional hip arthroplasty,15 the performance of these 
bearings on the general population is poor,16 making 
them an expensive lifetime choice. Debate continues 
around cemented versus cementless fixation, patient sur-
vival, and lifetime costs. However, much of the case against 
cementless stems using contemporaneous bearing materi-
als lies in additional implant cost and an increased risk of 
early periprosthetic fracture. Competitive pricing and 
advances in cementless implant design may also modulate 
these arguments in the future.
Where next?. Although drugs to prevent the progression 
of early arthritis, non-arthroplasty surgery, and regenera-
tive medicine solutions to established disease will be real-
istic prospects for the future, our current best solution for 
advanced OA that does not respond to lifestyle measures 
and analgesics remains hip arthroplasty. Although non-
conventional choices will remain for some, the major-
ity of patients will have fewer choices as they are being 
cared for in a healthcare economy that has to balance 
cost against long-term survival.
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